Identification of deletion-junction site of CYP2A6*4B allele lacking entire coding region of CYP2A6 in Japanese

被引：14

作者：

Ariyoshi, N

Sekine, H

Nakayama, K

Saito, K

Miyamoto, A

Kamataki, T

机构：

[1] Hokkaido Univ, Grad Sch Pharmaceut Sci, Dept Pharmacobiodynam, Lab Drug Metab, Sapporo, Hokkaido 060, Japan

[2] Sapporo Med Univ, Div Pharmaceut Hlth Care & Sci, Sapporo, Hokkaido, Japan

来源：

PHARMACOGENETICS | 2004年 / 14卷 / 10期

关键词：

cytochrome P450; genetic polymorphism; genotyping;

D O I：

10.1097/00008571-200410000-00008

中图分类号：

Q81 [生物工程学（生物技术）]; Q93 [微生物学];

学科分类号：

071005 ; 0836 ; 090102 ; 100705 ;

摘要：

[No abstract available]

引用

页码：701 / 705

页数：5

共 9 条

[1] Characterization of a genotype previously designated as CYP2A6 D-type:: CYP2A6*4B, another entire gene deletion allele of the CYP2A6 gene in Japanese [J].

Ariyoshi, N ;

Sekine, H ;

Saito, K ;

Kamataki, T .

PHARMACOGENETICS, 2002, 12 (06) :501-504

[2] Structural characterization of a new variant of the CYP2A6 gene (CYP2A6*1B) apparently diagnosed as heterozygotes of CYP2A6*1A and CYP2A6*4C [J].

Ariyoshi, N ;

Takahashi, Y ;

Miyamoto, M ;

Umetsu, Y ;

Daigo, S ;

Tateishi, T ;

Kobayashi, S ;

Mizorogi, Y ;

Loriot, MA ;

Stücker, I ;

Beaune, P ;

Kinoshita, M ;

Kamataki, T .

PHARMACOGENETICS, 2000, 10 (08) :687-693

[3]

Ikeda K, 2000, CLIN CANCER RES, V6, P4409

[4] CYP2A6 gene deletion reduces susceptibility to lung cancer [J].

Miyamoto, M ;

Umetsu, Y ;

Dosaka-Akita, H ;

Sawamura, Y ;

Yokota, J ;

Kunitoh, H ;

Nemoto, N ;

Sato, K ;

Ariyoshi, N ;

Kamataki, T .

BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, 1999, 261 (03) :658-660

[5] Homologous unequal cross-over within the human CYP2A gene cluster as a mechanism for the deletion of the entire CYP2A6 gene associated with the poor metabolizer phenotype [J].

Nunoya, K ;

Yokoi, T ;

Takahashi, Y ;

Kimura, K ;

Kinoshita, M ;

Kamataki, T .

JOURNAL OF BIOCHEMISTRY, 1999, 126 (02) :402-407

[6] A new deleted allele in the human cytochrome P450 2A6 (CYP2A6) gene found in individuals showing poor metabolic capacity to coumarin and (+)-cis-3,5-dimethyl-2-(3-pyridyl)thiazolidin-4-one hydrochloride (SM-12502) [J].

Nunoya, K ;

Yokoi, T ;

Kimura, K ;

Inoue, K ;

Kodama, T ;

Funayama, M ;

Nagashima, K ;

Funae, Y ;

Green, C ;

Kinoshita, M ;

Kamataki, T .

PHARMACOGENETICS, 1998, 8 (03) :239-249

[7]

Nunoya KI, 1996, J PHARMACOL EXP THER, V277, P768

[8] Identification and characterisation of novel polymorphisms in the CYP2A locus:: implications for nicotine metabolism [J].

Oscarson, M ;

McLellan, RA ;

Gullstén, H ;

Agúndez, JAG ;

Benítez, J ;

Rautio, A ;

Raunio, H ;

Pelkonen, O ;

Ingelman-Sundberg, M .

FEBS LETTERS, 1999, 460 (02) :321-327

[9] Characterisation and PCR-based detection of a CYP2A6 gene deletion found at a high frequency in a Chinese population [J].

Oscarson, M ;

McLellan, RA ;

Gullstén, H ;

Yue, QY ;

Lang, MA ;

Bernal, ML ;

Sinues, B ;

Hirvonen, A ;

Raunio, H ;

Pelkonen, O ;

Ingelman-Sundberg, M .

FEBS LETTERS, 1999, 448 (01) :105-110

← 1 →